Literature DB >> 1201765

Fatty acid pattern of lipids in normal and dystrophic human muscle.

D Kunze, G Reichmann, E Egger, D Olthoff, K Döhler.   

Abstract

The fatty acid distribution of the main lipid fractions: triglycerides (TG), phosphatidylcholine (PCh), phosphatidylethanolamine (PE), and sphingomyelin (Sph) of muscle from 6 patients with progressive muscular dystrophy (p.m.d.), Duchenne, 8 to 12 years old was estimated and compared with normal controls of different age. In view of the results of several authors about varied fatty acid distribution in immature muscle a third group comprising samples of neonatal muscle was studied. 1. The fatty acid pattern of the lipid fractions TG, Sph, and PE from muscle of patients with p.m.d. shows no important variation in comparison to normal controls. In contrast to this the fatty acid distribution in PCh is extremely varied: the percentage of 18:2 is decreased and corrrespondingly the content of 18:1 is increased. In view of the high percentage (nearly 10%) in which linoleic acid is substituted by oleic acid in PCh, effects on the plasma membrane are to be expected. 2. The fatty acid pattern in neonatal muscle shows in narly all positions of the fractions TG, Sph, PE, and PCh a different distribution from normal or dystrophic muscle. In view of the most important variation in dystrophic muscle it must be stated that generally 18:2 is decreased. This deficit was replaced by an increase of all other fatty acids (not only at a substitution by 18:1 as given in p.m.d.). Therefore the diminished content of linoleic acid in PCh of neonatal and dystrophic muscle cannot be interpreted as expression of a corresponding or similar lipid metabolism in both tissues. The results were seen as signs of significant qualitative alterations especially of PCh in p.m.d. They were discussed as proof of our thesis that the basic defect in p.m.d. concerns the specific acylation of PCh with linoleic acid.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1201765     DOI: 10.1111/j.1365-2362.1975.tb00479.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

2.  Skeletal-muscle sarcolemma from normal and dystrophic mice. Isolation, characterization and lipid composition.

Authors:  T A de Kretser; B G Livett
Journal:  Biochem J       Date:  1977-11-15       Impact factor: 3.857

3.  Lipid mapping in human dystrophic muscle by cluster-time-of-flight secondary ion mass spectrometry imaging.

Authors:  Nora Tahallah; Alain Brunelle; Sabine De La Porte; Olivier Laprévote
Journal:  J Lipid Res       Date:  2007-11-17       Impact factor: 5.922

4.  Lipid composition and catalytic properties of sarcoplasmic reticulum from normal and dystrophic chicken muscle.

Authors:  A M Tovar; S Verjovski-Almeida
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

5.  Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy.

Authors:  B B Gelman; L Papa; M H Davis; E Gruenstein
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

6.  Lipidomic Analyses Reveal Specific Alterations of Phosphatidylcholine in Dystrophic Mdx Muscle.

Authors:  William J Valentine; Sherif A Mostafa; Suzumi M Tokuoka; Fumie Hamano; Natsuko F Inagaki; Joel Z Nordin; Norio Motohashi; Yoshihiro Kita; Yoshitsugu Aoki; Takao Shimizu; Hideo Shindou
Journal:  Front Physiol       Date:  2022-01-12       Impact factor: 4.566

7.  Plasma lipidomic analysis shows a disease progression signature in mdx mice.

Authors:  Roula Tsonaka; Alexandre Seyer; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.